Vaxcyte has appointed John Furey to its Board of Directors. He currently serves as CEO of Imvax, a clinical-stage biotechnology company developing novel immunotherapies for cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCVX: